ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD) (SPARTA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01983241
Recruitment Status : Recruiting
First Posted : November 13, 2013
Last Update Posted : March 5, 2018
Sponsor:
Information provided by (Responsible Party):
Grifols Therapeutics LLC

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : August 2021
  Estimated Study Completion Date : August 2021